Data from Experimental Lung Metastases in Mice Are More Effectively Inhibited by Blockade of IL23R than IL23

Abstract

<div>Abstract<p>Tumor-induced immunosuppression is mediated through various mechanisms including engagement of immune checkpoint receptors on effector cells, function of immunoregulatory cells such as regulatory T cells and myeloid-derived suppressor cells, and deployment of immunosuppressive cytokines such as TGFβ and IL10. IL23 is a cytokine that negatively affects antitumor immunity. In this study, we investigated whether IL23-deficient (IL23p19<sup>−/−</sup>) and IL23R-deficient (IL23R<sup>−/−</sup>) mice phenocopied each other, with respect to their tumor control. We found that IL23R<sup>−/−</sup> mice had significantly fewer lung metastases compared with IL23p19<sup>−/−</sup> mice across three different experimental lung metastasis models (B16F10, LWT1, and RM-1). Similarly, IL23R blocking antibodies were more effective than antibodies neutralizing IL23 in suppressing experimental lung metastases. The antimetastatic activity of anti-IL23R was dependent on NK cells and IFNγ but independent of CD8<sup>+</sup> T cells, CD4<sup>+</sup> T cells, activating Fc receptors, and IL12. Furthermore, our data suggest this increased antitumor efficacy was due to an increase in the proportion of IFNγ-producing NK cells in the lungs of B16F10 tumor-bearing mice. Anti-IL23R, but not anti-IL23p19, partially suppressed lung metastases in tumor-bearing mice neutralized for IL12p40. Collectively, our data imply that IL23R has tumor-promoting effects that are partially independent of IL23p19. Blocking IL23R may be more effective than neutralizing IL23 in the suppression of tumor metastases. <i>Cancer Immunol Res; 6(8); 978–87. ©2018 AACR</i>.</p></div>